0001209191-23-016391.txt : 20230306
0001209191-23-016391.hdr.sgml : 20230306
20230306170759
ACCESSION NUMBER: 0001209191-23-016391
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230224
FILED AS OF DATE: 20230306
DATE AS OF CHANGE: 20230306
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Fontenot Jason D.
CENTRAL INDEX KEY: 0001851761
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30171
FILM NUMBER: 23709821
MAIL ADDRESS:
STREET 1: 7000 MARINA BLVD
CITY: BRISBANE
STATE: CA
ZIP: 94005
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC
CENTRAL INDEX KEY: 0001001233
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 680359556
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7000 MARINA BLVD
CITY: BRISBANE
STATE: CA
ZIP: 94005
BUSINESS PHONE: 5109706000
MAIL ADDRESS:
STREET 1: 7000 MARINA BLVD
CITY: BRISBANE
STATE: CA
ZIP: 94005
FORMER COMPANY:
FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC
DATE OF NAME CHANGE: 20000208
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-02-24
0
0001001233
SANGAMO THERAPEUTICS, INC
SGMO
0001851761
Fontenot Jason D.
C/O SANGAMO THERAPEUTICS, INC.
7000 MARINA BLVD.
BRISBANE
CA
94005
0
1
0
0
SVP, Chief Scientific Officer
Common Stock
2023-02-24
4
A
0
42750
0.00
A
145917
D
Common Stock
2023-02-25
4
F
0
6559
2.66
D
139358
D
Stock Option (Right to Buy)
2.66
2023-02-24
4
A
0
199500
0.00
A
2033-02-23
Common Stock
199500
199500
D
Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through each such date and subject to acceleration as provided in the 2018 EIP.
Represents shares underlying the portions of RSU grants that vested on February 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 24, 2023 of $2.66/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.
Includes: (a) 6,306 shares resulting from the February 25, 2023 final vesting installment of the Reporting Person's February 25, 2020 RSU grant, (b) 5,548 shares resulting from the February 25, 2023 vesting installment of the Reporting Person's February 25, 2021 RSU grant and 7,344 shares subject to such RSU grant that will vest in one final installment on February 25, 2024, and (c) 8,530 shares resulting from the February 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 33,825 shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
Jason D. Fontenot, by /s/ Ron A. Metzger, Attorney-in-Fact
2023-03-06